SWOG clinical trial number
SWOG-8956
Study of Cisplatin and 5-FU Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder
Closed
Phase
Accrual
63%
Published
Abbreviated Title
Study of Cisplatin and 5-FU Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder
Activated
10/01/1990
Closed
06/15/1993
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1997
Continuous infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: A Southwest Oncology Group trial.
High dose cisplatin (C) and continuous infusion 5 fluorouracil (5FU CI) for the treatment of advanced/recurrent transitional cell cancer of the bladder (ARTCCB). Final report of a Southwest Oncology Group (SWOG) trial.
1993
Evaluation of cisplatin + 5 fluorouracil infusion for advanced/metastatic transitional cell carcinoma of the bladder. (AMTCCB). A Southwest Oncology Group study.
1992
Significant response rate to cisplatin + 5-fluorouracil in advanced/recurrent bladder cancer. A preliminary report. A Southwest Oncology Group study.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase